Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment

Open-Label Study to Evaluate the Efficacy and Safety of SCY-078 (Ibrexafungerp) in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment (FURI)

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03059992

Acronym

FURI

Enrollment

233

Registered

2017-02-23

Start date

2017-04-01

Completion date

2023-08-25

Last updated

2024-11-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic Bronchopulmonary Aspergillosis, Blastomycosis, Chronic Pulmonary Aspergillosis, Coccidioidomycosis, Histoplasmosis, Invasive Candidiasis, Invasive Pulmonary Aspergillosis, Mucocutaneous Candidiasis, Other Emerging Fungi, Recurrent Vulvovaginal Candidiasis

Brief summary

This is a multicenter, open label, non-comparator, single arm study to evaluate the efficacy and safety of ibrexafungerp (SCY-078) in patients ≥ 18 years of age with a documented fungal disease that has been intolerant or refractory (rIFI) to Standard of Care (SoC) antifungal treatment.

Detailed description

This is a multicenter, open label, non-comparator, single arm study to evaluate the efficacy and safety of ibrexafungerp in patients ≥ 18 years of age with a documented invasive and/or severe fungal disease that has been intolerant or refractory (rIFI) to Standard of Care (SoC) antifungal treatment. Patients will be treated with ibrexafungerp for up to 180 days. Treatment beyond 180 days and combination therapy with other antifungal agents may be allowed under special circumstances to be agreed upon by the Investigator and the Sponsor. Subjects must have a proven or probable fungal disease and meet all study criteria to be considered for enrollment. Eligible subjects must also have documented evidence of failure of, intolerance to, or toxicity related to a currently approved SoC antifungal treatment. Subjects will also be considered for enrollment if they have an eligible fungal disease and, in the judgement of the investigator, the subject cannot receive approved oral antifungal options (e.g. susceptibility of the organism or risk for drug-drug interactions) and a continued IV antifungal therapy is not desirable or feasible due to clinical or logistical circumstances. Following a screening visit, there will be up to 15 treatment visits, a follow-up visit and 2 follow-up contacts.

Interventions

DRUGIbrexafungerp

Experimental Study Drug

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Intervention model description

Open label, non-comparator, single arm

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Key Inclusion Criteria: 1. Must have a documented eligible invasive and/or severe fungal disease that is refractory or intolerant to Standard-of-Care treatment 2. Be able to tolerate medication orally or through a nasogastric (NG) tube or percutaneous endoscopic gastrostomy (PEG) tube 3. Be able to understand and sign a written informed consent form (ICF), which must be obtained prior to treatment and any study-related procedures. 4. Be able to understand and sign a consent or authorization form which shall permit the use, disclosure and transfer of the subject's personal health information. (e.g., in the U.S. HIPAA Authorization form). 5. Be able to understand and follow all study-related procedures including study drug administration. 6. Agree to use a medically acceptable method of contraception while receiving protocol-assigned product. Key

Exclusion criteria

1. An invasive fungal disease with CNS involvement. 2. Subject has an inappropriately controlled fungal disease source (e.g., persistent catheters that cannot be removed and are likely the source of infection). 3. Subject is hemodynamically unstable, requiring vasopressor medication for blood pressure support. 4. A life expectancy \< 30 days. 5. Subject with abnormal liver test parameters: aspartate aminotransferase (AST), alanine aminotransferase (ALT) \>10 x the upper limit of normal (ULN), and/or total bilirubin \> 5 x ULN. 6. Subject is pregnant or lactating. 7. Subject has used an investigational drug within 30 days prior to the baseline visit.

Design outcomes

Primary

Measure	Time frame	Description
Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Vulvovaginal Candidiasis: Day 17. Chronic Mucocutaneous Candidiasis: EOT up to Day 84. Chronic Pulmonary Aspergillus and Allergic Bronchopulmonary Aspergillosis: EOT up to Day 90. All other diseases: EOT up to Day 180. All Days measured from Baseline.	The percentage of participants who achieve Global Response (defined as complete or partial response) as determined by the DRC at disease specific timepoints by fungal disease. Global Response is measured by participant survival and overall effect of treatment on the disease. Complete response: Survival, all attributable signs/symptoms (including radiological) resolved and myoclogical eradication of disease; Partial response: Survival, improvement of attributable signs/symptoms (including radiological). Disease specific timepoints: End of Treatment (EoT) for invasive candidiasis, EoT or Day 84 for Chronic Mucocutaneous Candidiasis, Test of Cure (TOC) for Vulvovaginal Candidiasis, EoT or Day 90 for Chronic Pulmonary Aspergillosis, EoT or Day 90 Allergic Bronchopulmonary Aspergillosis and EoT for all other diseases.

Secondary

Measure	Time frame	Description
Describe Ibrexafungerp Plasma Concentrations	Day 2 post-dose, Day 3-5 pre-dose, Dat 7-10 pre-dose.	Ibrexafungerp plasma concentrations measured at specified timepoints prior to and after administration of study drug for participants that received the following dose regimen: Day 1 and 2 loading dose - 750mg BID Day 3 onwards - 750mg QD
Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Enrollment Category	Vulvovaginal Candidiasis: Day 17. Chronic Mucocutaneous Candidiasis: EOT up to Day 84. Chronic Pulmonary Aspergillus and Allergic Bronchopulmonary Aspergillosis: EOT up to Day 90. All other diseases: EOT up to Day 180. All Days measured from Baseline.	The percentage of participants who achieve a Global Response (defined as complete or partial response) as determined by the DRC by enrollment category, at disease specific timepoints. Global Response is measured by participant survival and overall effect of treatment on the disease. Complete response: Survival, all attributable signs/symptoms (including radiological) resolved and myoclogical eradication of disease; Partial response: Survival, improvement of attributable signs/symptoms (including radiological). Disease specific timepoints: End of Treatment (EoT) for invasive candidiasis, EoT or Day 84 for Chronic Mucocutaneous Candidiasis, Test of Cure (TOC) for Vulvovaginal Candidiasis, EoT or Day 90 for Chronic Pulmonary Aspergillosis, EoT or Day 90 Allergic Bronchopulmonary Aspergillosis and EoT for all other diseases. Participants may have been enrolled for more than 1 enrollment reason.
Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Disease Category.	Vulvovaginal Candidiasis: Day 17. Chronic Mucocutaneous Candidiasis: EOT up to Day 84. Chronic Pulmonary Aspergillus and Allergic Bronchopulmonary Aspergillosis: EOT up to Day 90. All other diseases: EOT up to Day 180. All Days measured from Baseline.	The percentage of participants who achieve Global Response (defined as complete or partial response) as determined by the DRC at disease specific timepoints by disease category. Global Response is measured by participant survival and overall effect of treatment on the disease. Complete response: Survival, all attributable signs/symptoms (including radiological) resolved and myoclogical eradication of disease; Partial response: Survival, improvement of attributable signs/symptoms (including radiological). Disease specific timepoints: End of Treatment (EoT) for invasive candidiasis, EoT or Day 84 for Chronic Mucocutaneous Candidiasis, Test of Cure (TOC) for Vulvovaginal Candidiasis, EoT or Day 90 for Chronic Pulmonary Aspergillosis, EoT or Day 90 Allergic Bronchopulmonary Aspergillosis and EoT for all other diseases.
Percentage of Participants With a Clinical Response (Based on Signs and Symptoms) by Disease Category	Vulvovaginal Candidiasis: Day 17. Chronic Mucocutaneous Candidiasis: EOT up to Day 84. Chronic Pulmonary Aspergillus and Allergic Bronchopulmonary Aspergillosis: EOT up to Day 90. All other diseases: EOT up to Day 180. All Days measured from Baseline.	The percentage of participants with a Clinical Response as determined by the DRC at disease specific timepoints, by disease category. Clinical Response: resolution or improvement in attributable symptoms and signs of disease and radiological abnormalities (if applicable) . Disease specific timepoints: End of Treatment (EoT) for invasive candidiasis, EoT or Day 84 for Chronic Mucocutaneous Candidiasis, Test of Cure (TOC) for Vulvovaginal Candidiasis, EoT or Day 90 for Chronic Pulmonary Aspergillosis, EoT or Day 90 Allergic Bronchopulmonary Aspergillosis and EoT for all other diseases. Clinical response was evaluated based on disease signs (including radiological signs) and symptoms.
Percentage of Participants With a Clinical Response (Signs and Symptoms) by Disease Category and Pathogen	Vulvovaginal Candidiasis: Day 17. Chronic Mucocutaneous Candidiasis: EOT up to Day 84. Chronic Pulmonary Aspergillus and Allergic Bronchopulmonary Aspergillosis: EOT up to Day 90. All other diseases: EOT up to Day 180. All Days measured from Baseline.	The percentage of participants with a Clinical Response as determined by the DRC by disease category and by pathogen isolated, at disease specific timepoints. Clinical Response: resolution or improvement in attributable symptoms and signs of disease and radiological abnormalities (if applicable) . Disease specific timepoints: End of Treatment (EoT) for invasive candidiasis, EoT or Day 84 for Chronic Mucocutaneous Candidiasis, Test of Cure (TOC) for Vulvovaginal Candidiasis, EoT or Day 90 for Chronic Pulmonary Aspergillosis, EoT or Day 90 Allergic Bronchopulmonary Aspergillosis and EoT for all other diseases. Clinical response was evaluated based on disease signs (including radiological signs) and symptoms.
Percentage of Participants With a Clinical Response (Signs and Symptoms) by Fungal Disease	Vulvovaginal Candidiasis: Day 17. Chronic Mucocutaneous Candidiasis: EOT up to Day 84. Chronic Pulmonary Aspergillus and Allergic Bronchopulmonary Aspergillosis: EOT up to Day 90. All other diseases: EOT up to Day 180. All Days measured from Baseline.	The percentage of participants with a Clinical Response as determined by the DRC by fungal disease, at disease specific timepoints. Clinical Response: resolution or improvement in attributable symptoms and signs of disease and radiological abnormalities (if applicable) . Disease specific timepoints: End of Treatment (EoT) for invasive candidiasis, EoT or Day 84 for Chronic Mucocutaneous Candidiasis, Test of Cure (TOC) for Vulvovaginal Candidiasis, EoT or Day 90 for Chronic Pulmonary Aspergillosis, EoT or Day 90 Allergic Bronchopulmonary Aspergillosis and EoT for all other diseases. Clinical response was evaluated based on disease signs (including radiological signs) and symptoms.
Time to Death From Any Cause	Six weeks after End of Treatment (EOT). EOT for Vulvovaginal Candidiasis is Day 7, Chronic Mucocutaneous Candidiasis is up to Day 84, Chronic Pulmonary Aspergillus and Allergic Bronchopulmonary Aspergillosis is up to Day 90 and up to Day 180 for other.	Time to death from any cause in days per Fungal Disease
Percentage of Participants With a Mycological Response by Disease Category	Vulvovaginal Candidiasis: Day 17. Chronic Mucocutaneous Candidiasis: EOT up to Day 84. Chronic Pulmonary Aspergillus and Allergic Bronchopulmonary Aspergillosis: EOT up to Day 90. All other diseases: EOT up to Day 180. All Days measured from Baseline.	The percentage of participants with a Mycological Response as determined by the DRC by disease category, at disease specific timepoints. Mycological Response: evidence of eradication or clearance of cultures or reduction of fungal burden, as assessed by a quantitative and validated laboratory marker. Disease specific timepoints: End of Treatment (EoT) for invasive candidiasis, EoT or Day 84 for Chronic Mucocutaneous Candidiasis, Test of Cure (TOC) for Vulvovaginal Candidiasis, EoT or Day 90 for Chronic Pulmonary Aspergillosis, EoT or Day 90 Allergic Bronchopulmonary Aspergillosis and EoT for all other diseases. Mycological response was evaluated based on culture, microscopy and other biomarkers of fungal infection.
Percentage of Participants With a Mycological Response by Disease Category and Pathogen	Vulvovaginal Candidiasis: Day 17. Chronic Mucocutaneous Candidiasis: EOT up to Day 84. Chronic Pulmonary Aspergillus and Allergic Bronchopulmonary Aspergillosis: EOT up to Day 90. All other diseases: EOT up to Day 180. All Days measured from Baseline.	The percentage of participants with a Mycological Response as determined by the DRC by disease category and by pathogen, at disease specific timepoints. Mycological Response: evidence of eradication or clearance of cultures or reduction of fungal burden, as assessed by a quantitative and validated laboratory marker. Disease specific timepoints: End of Treatment (EoT) for invasive candidiasis, EoT or Day 84 for Chronic Mucocutaneous Candidiasis, Test of Cure (TOC) for Vulvovaginal Candidiasis, EoT or Day 90 for Chronic Pulmonary Aspergillosis, EoT or Day 90 Allergic Bronchopulmonary Aspergillosis and EoT for all other diseases. Mycological response was evaluated based on culture, microscopy and other biomarkers of fungal infection.
Percentage of Participants With a Mycological Response by Fungal Disease	Vulvovaginal Candidiasis: Day 17. Chronic Mucocutaneous Candidiasis: EOT up to Day 84. Chronic Pulmonary Aspergillus and Allergic Bronchopulmonary Aspergillosis: EOT up to Day 90. All other diseases: EOT up to Day 180. All Days measured from Baseline.	The percentage of participants with a Mycological Response as determined by the DRC by fungal disease, at disease specific timepoints. Mycological Response: evidence of eradication or clearance of cultures or reduction of fungal burden, as assessed by a quantitative and validated laboratory marker. Disease specific timepoints: End of Treatment (EoT) for invasive candidiasis, EoT or Day 84 for Chronic Mucocutaneous Candidiasis, Test of Cure (TOC) for Vulvovaginal Candidiasis, EoT or Day 90 for Chronic Pulmonary Aspergillosis, EoT or Day 90 Allergic Bronchopulmonary Aspergillosis and EoT for all other diseases. Mycological response was evaluated based on culture, microscopy and other biomarkers of fungal infection.
Percentage of Participants With a Mycological Response by Enrollment Category	Vulvovaginal Candidiasis: Day 17. Chronic Mucocutaneous Candidiasis: EOT up to Day 84. Chronic Pulmonary Aspergillus and Allergic Bronchopulmonary Aspergillosis: EOT up to Day 90. All other diseases: EOT up to Day 180. All Days measured from Baseline.	The percentage of participants with a Mycological Response as determined by the DRC by enrollment category, at disease specific timepoints. Mycological Response: evidence of eradication or clearance of cultures or reduction of fungal burden, as assessed by a quantitative and validated laboratory marker. Disease specific timepoints: End of Treatment (EoT) for invasive candidiasis, EoT or Day 84 for Chronic Mucocutaneous Candidiasis, Test of Cure (TOC) for Vulvovaginal Candidiasis, EoT or Day 90 for Chronic Pulmonary Aspergillosis, EoT or Day 90 Allergic Bronchopulmonary Aspergillosis and EoT for all other diseases. Mycological response was evaluated based on culture, microscopy and other biomarkers of fungal infection.
Percentage of Participants With a Recurrence of Baseline Fungal Disease	42 days for vulvovaginal candidiasis and 6 weeks after End of Treatment (up to 180 days after treatment start) for all other diseases.	The percentage of participants with a recurrence of their baseline fungal disease as assessed by the DRC at the 25-Day Follow Up (FU) for Vulvovaginal Candidiasis and at the 6-Week FU for all other diseases as assessed by the DRC. Recurrence is defined as having Global Response at end of treatment or test of cure, but re-emergence of the baseline fungal disease during the post treatment follow-up. Re-emergence is required to be with the same species and involving the same site identified at baseline.
Percentage of Participants Surviving at Day 30 or Day 42	Day 30 post-Baseline for Invasive Candidiasis and Day 42 post-Baseline for all other fungal diseases.	Percentage of participants with invasive candidiasis surviving at Day 30 post-Baseline or percentage of participants with other fungal diseases surviving at Day 42 post-Baseline.
Percentage of Participants With a Clinical Response (Signs and Symptoms) by Enrollment Category	Vulvovaginal Candidiasis: Day 17. Chronic Mucocutaneous Candidiasis: EOT up to Day 84. Chronic Pulmonary Aspergillus and Allergic Bronchopulmonary Aspergillosis: EOT up to Day 90. All other diseases: EOT up to Day 180. All Days measured from Baseline.	The percentage of participants with a Clinical Response as determined by the DRC by enrollment category, at disease specific timepoints. Clinical Response: resolution or improvement in attributable symptoms and signs of disease and radiological abnormalities (if applicable) . Disease specific timepoints: End of Treatment (EoT) for invasive candidiasis, EoT or Day 84 for Chronic Mucocutaneous Candidiasis, Test of Cure (TOC) for Vulvovaginal Candidiasis, EoT or Day 90 for Chronic Pulmonary Aspergillosis, EoT or Day 90 Allergic Bronchopulmonary Aspergillosis and EoT for all other diseases. Clinical response was evaluated based on disease signs (including radiological signs) and symptoms.

Countries

Austria, Germany, Netherlands, Pakistan, South Africa, Spain, United Kingdom, United States

Participant flow

Participants by arm

Arm	Count
Ibrexafungerp (SCY-078) Ibrexafungerp (SCY-078), orally administered QD for up to 180 days.	233
Total	233

Baseline characteristics

Characteristic	Ibrexafungerp (SCY-078)
Age, Continuous	53.6 years STANDARD_DEVIATION 16.23
Ethnicity (NIH/OMB) Hispanic or Latino	10 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	219 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	4 Participants
Race (NIH/OMB) American Indian or Alaska Native	3 Participants
Race (NIH/OMB) Asian	16 Participants
Race (NIH/OMB) Black or African American	29 Participants
Race (NIH/OMB) More than one race	1 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants
Race (NIH/OMB) Unknown or Not Reported	4 Participants
Race (NIH/OMB) White	180 Participants
Sex: Female, Male Female	128 Participants
Sex: Female, Male Male	105 Participants

Adverse events

Event type	EG000 affected / at risk
deaths Total, all-cause mortality	15 / 233
other Total, other adverse events	215 / 233
serious Total, serious adverse events	102 / 233

Outcome results

Primary

Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.

The percentage of participants who achieve Global Response (defined as complete or partial response) as determined by the DRC at disease specific timepoints by fungal disease. Global Response is measured by participant survival and overall effect of treatment on the disease. Complete response: Survival, all attributable signs/symptoms (including radiological) resolved and myoclogical eradication of disease; Partial response: Survival, improvement of attributable signs/symptoms (including radiological). Disease specific timepoints: End of Treatment (EoT) for invasive candidiasis, EoT or Day 84 for Chronic Mucocutaneous Candidiasis, Test of Cure (TOC) for Vulvovaginal Candidiasis, EoT or Day 90 for Chronic Pulmonary Aspergillosis, EoT or Day 90 Allergic Bronchopulmonary Aspergillosis and EoT for all other diseases.

Time frame: Vulvovaginal Candidiasis: Day 17. Chronic Mucocutaneous Candidiasis: EOT up to Day 84. Chronic Pulmonary Aspergillus and Allergic Bronchopulmonary Aspergillosis: EOT up to Day 90. All other diseases: EOT up to Day 180. All Days measured from Baseline.

Population: Intent to Treat (ITT) Population - all participants who were enrolled in the study and received at least one dose of study drug.~Per Protocol (PP) Population - include all ITT participants who received enough study drug to enable clinical efficacy judgement as determined by the DRC, who have an EOT or TOC (as applicable) assessment and who have no major protocol violations that could impact the assessment of efficacy.

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Overall Study (ITT)	Success	142 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Overall Study (ITT)	Failure	69 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Overall Study (ITT)	Not Evaluable	22 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Overall Study (PP)	Success	131 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Overall Study (PP)	Failure	59 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Overall Study (PP)	Not Evaluable	5 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Acute Invasive Candidiasis including Candidemia (ITT)	Success	40 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Acute Invasive Candidiasis including Candidemia (ITT)	Failure	13 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Acute Invasive Candidiasis including Candidemia (ITT)	Not Evaluable	8 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Acute Invasive Candidiasis including Candidemia (PP)	Success	37 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Acute Invasive Candidiasis including Candidemia (PP)	Failure	10 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Acute Invasive Candidiasis including Candidemia (PP)	Not Evaluable	2 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Chronic Invasive Candidiasis (ITT)	Success	30 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Chronic Invasive Candidiasis (ITT)	Failure	9 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Chronic Invasive Candidiasis (ITT)	Not Evaluable	4 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Chronic Invasive Candidiasis (PP)	Success	25 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Chronic Invasive Candidiasis (PP)	Failure	7 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Chronic Invasive Candidiasis (PP)	Not Evaluable	1 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Esophageal Candidiasis (ITT)	Success	9 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Esophageal Candidiasis (ITT)	Failure	5 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Esophageal Candidiasis (ITT)	Not Evaluable	2 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Esophageal Candidiasis (PP)	Success	9 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Esophageal Candidiasis (PP)	Failure	4 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Esophageal Candidiasis (PP)	Not Evaluable	1 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Oropharyngeal Candidiasis (ITT)	Success	9 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Oropharyngeal Candidiasis (ITT)	Failure	5 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Oropharyngeal Candidiasis (ITT)	Not Evaluable	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Oropharyngeal Candidiasis (PP)	Success	8 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Oropharyngeal Candidiasis (PP)	Failure	5 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Oropharyngeal Candidiasis (PP)	Not Evaluable	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Chronic Mucocutaneous Candidiasis (ITT)	Success	8 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Chronic Mucocutaneous Candidiasis (ITT)	Failure	5 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Chronic Mucocutaneous Candidiasis (ITT)	Not Evaluable	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Chronic Mucocutaneous Candidiasis (PP)	Success	8 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Chronic Mucocutaneous Candidiasis (PP)	Failure	4 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Chronic Mucocutaneous Candidiasis (PP)	Not Evaluable	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Vulvovaginal Candidiasis (ITT)	Success	26 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Vulvovaginal Candidiasis (ITT)	Failure	4 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Vulvovaginal Candidiasis (ITT)	Not Evaluable	2 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Vulvovaginal Candidiasis (PP)	Success	24 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Vulvovaginal Candidiasis (PP)	Failure	3 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Vulvovaginal Candidiasis (PP)	Not Evaluable	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Disseminated/Invasive Dimorphic Fungi (ITT)	Success	1 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Disseminated/Invasive Dimorphic Fungi (ITT)	Failure	2 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Disseminated/Invasive Dimorphic Fungi (ITT)	Not Evaluable	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Disseminated/Invasive Dimorphic Fungi (PP)	Success	1 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Disseminated/Invasive Dimorphic Fungi (PP)	Failure	2 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Disseminated/Invasive Dimorphic Fungi (PP)	Not Evaluable	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Chronic Pulmonary Aspergillosis (ITT)	Success	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Chronic Pulmonary Aspergillosis (ITT)	Failure	6 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Chronic Pulmonary Aspergillosis (ITT)	Not Evaluable	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Chronic Pulmonary Aspergillosis (PP)	Success	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Chronic Pulmonary Aspergillosis (PP)	Failure	5 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Chronic Pulmonary Aspergillosis (PP)	Not Evaluable	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Allergic Bronchopulmonary Aspergillosis (ITT)	Success	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Allergic Bronchopulmonary Aspergillosis (ITT)	Failure	3 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Allergic Bronchopulmonary Aspergillosis (ITT)	Not Evaluable	2 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Allergic Bronchopulmonary Aspergillosis (PP)	Success	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Allergic Bronchopulmonary Aspergillosis (PP)	Failure	3 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Allergic Bronchopulmonary Aspergillosis (PP)	Not Evaluable	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Invasive Pulmonary Aspergillosis (ITT)	Success	12 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Invasive Pulmonary Aspergillosis (ITT)	Failure	14 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Invasive Pulmonary Aspergillosis (ITT)	Not Evaluable	3 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Invasive Pulmonary Aspergillosis (PP)	Success	12 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Invasive Pulmonary Aspergillosis (PP)	Failure	13 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Invasive Pulmonary Aspergillosis (PP)	Not Evaluable	1 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Other Emerging Fungi (ITT)	Success	7 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Other Emerging Fungi (ITT)	Failure	3 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Other Emerging Fungi (ITT)	Not Evaluable	1 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Other Emerging Fungi (PP)	Success	7 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Other Emerging Fungi (PP)	Failure	3 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.	Other Emerging Fungi (PP)	Not Evaluable	0 Participants

Secondary

Describe Ibrexafungerp Plasma Concentrations

Ibrexafungerp plasma concentrations measured at specified timepoints prior to and after administration of study drug for participants that received the following dose regimen: Day 1 and 2 loading dose - 750mg BID Day 3 onwards - 750mg QD

Time frame: Day 2 post-dose, Day 3-5 pre-dose, Dat 7-10 pre-dose.

Population: Pharmacokinetic (Pk) Population - all enrolled participants who provided at least one Pk sample and with no deviations significant enough to affect interpretation of the Pk data.

Arm	Measure	Group	Value (MEDIAN)
Ibrexafungerp (SCY-078)	Describe Ibrexafungerp Plasma Concentrations	Day 2 post-dose	479 nanograms per milliliter (ng/mL)
Ibrexafungerp (SCY-078)	Describe Ibrexafungerp Plasma Concentrations	Day 3-5 pre-dose	644 nanograms per milliliter (ng/mL)
Ibrexafungerp (SCY-078)	Describe Ibrexafungerp Plasma Concentrations	Day 7-10 pre-dose	571 nanograms per milliliter (ng/mL)

Secondary

Percentage of Participants Surviving at Day 30 or Day 42

Percentage of participants with invasive candidiasis surviving at Day 30 post-Baseline or percentage of participants with other fungal diseases surviving at Day 42 post-Baseline.

Time frame: Day 30 post-Baseline for Invasive Candidiasis and Day 42 post-Baseline for all other fungal diseases.

Population: Intent to Treat (ITT) Population - any participant enrolled in the study who received at least one dose of study drug.

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
Ibrexafungerp (SCY-078)	Percentage of Participants Surviving at Day 30 or Day 42	Candidemia	Dead	1 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Surviving at Day 30 or Day 42	Candidemia	Unknown	2 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Surviving at Day 30 or Day 42	Esophageal Candidiasis	Alive	15 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Surviving at Day 30 or Day 42	Acute Invasive Candidiasis	Alive	39 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Surviving at Day 30 or Day 42	Acute Invasive Candidiasis	Dead	1 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Surviving at Day 30 or Day 42	Acute Invasive Candidiasis	Unknown	1 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Surviving at Day 30 or Day 42	Chronic Invasive Candidiasis	Alive	43 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Surviving at Day 30 or Day 42	Chronic Invasive Candidiasis	Dead	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Surviving at Day 30 or Day 42	Chronic Invasive Candidiasis	Unknown	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Surviving at Day 30 or Day 42	Candidemia	Alive	17 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Surviving at Day 30 or Day 42	Esophageal Candidiasis	Dead	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Surviving at Day 30 or Day 42	Esophageal Candidiasis	Unknown	1 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Surviving at Day 30 or Day 42	Oropharyngeal Candidiasis	Alive	14 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Surviving at Day 30 or Day 42	Oropharyngeal Candidiasis	Dead	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Surviving at Day 30 or Day 42	Oropharyngeal Candidiasis	Unknown	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Surviving at Day 30 or Day 42	Chronic Mucocutaneous Candidiasis	Alive	13 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Surviving at Day 30 or Day 42	Chronic Mucocutaneous Candidiasis	Dead	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Surviving at Day 30 or Day 42	Chronic Mucocutaneous Candidiasis	Unknown	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Surviving at Day 30 or Day 42	Vulvovaginal Candidiasis	Alive	32 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Surviving at Day 30 or Day 42	Vulvovaginal Candidiasis	Dead	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Surviving at Day 30 or Day 42	Vulvovaginal Candidiasis	Unknown	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Surviving at Day 30 or Day 42	Disseminated/Invasive Dimorphic Fungi	Alive	3 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Surviving at Day 30 or Day 42	Disseminated/Invasive Dimorphic Fungi	Dead	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Surviving at Day 30 or Day 42	Disseminated/Invasive Dimorphic Fungi	Unknown	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Surviving at Day 30 or Day 42	Chronic Pulmonary Aspergillosis	Alive	5 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Surviving at Day 30 or Day 42	Chronic Pulmonary Aspergillosis	Dead	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Surviving at Day 30 or Day 42	Chronic Pulmonary Aspergillosis	Unknown	1 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Surviving at Day 30 or Day 42	Allergic Bronchopulmonary Aspergillosis	Alive	5 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Surviving at Day 30 or Day 42	Allergic Bronchopulmonary Aspergillosis	Dead	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Surviving at Day 30 or Day 42	Allergic Bronchopulmonary Aspergillosis	Unknown	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Surviving at Day 30 or Day 42	Invasive Pulmonary Aspergillosis	Alive	22 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Surviving at Day 30 or Day 42	Invasive Pulmonary Aspergillosis	Dead	6 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Surviving at Day 30 or Day 42	Invasive Pulmonary Aspergillosis	Unknown	1 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Surviving at Day 30 or Day 42	Other Emerging Fungi	Alive	10 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Surviving at Day 30 or Day 42	Other Emerging Fungi	Dead	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Surviving at Day 30 or Day 42	Other Emerging Fungi	Unknown	1 Participants

Secondary

Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Disease Category.

The percentage of participants who achieve Global Response (defined as complete or partial response) as determined by the DRC at disease specific timepoints by disease category. Global Response is measured by participant survival and overall effect of treatment on the disease. Complete response: Survival, all attributable signs/symptoms (including radiological) resolved and myoclogical eradication of disease; Partial response: Survival, improvement of attributable signs/symptoms (including radiological). Disease specific timepoints: End of Treatment (EoT) for invasive candidiasis, EoT or Day 84 for Chronic Mucocutaneous Candidiasis, Test of Cure (TOC) for Vulvovaginal Candidiasis, EoT or Day 90 for Chronic Pulmonary Aspergillosis, EoT or Day 90 Allergic Bronchopulmonary Aspergillosis and EoT for all other diseases.

Population: Intent to Treat (ITT) Population - all participants who were enrolled in the study and received at least one dose of study drug.

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Disease Category.	Invasive Candidiasis including Candidemia	Success	70 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Disease Category.	Invasive Candidiasis including Candidemia	Failure	22 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Disease Category.	Invasive Candidiasis including Candidemia	Not Evaluable	12 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Disease Category.	Mucocutaneous Candidiasis	Success	52 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Disease Category.	Mucocutaneous Candidiasis	Failure	19 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Disease Category.	Mucocutaneous Candidiasis	Not Evaluable	4 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Disease Category.	Dimorphic Fungi	Success	1 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Disease Category.	Dimorphic Fungi	Failure	2 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Disease Category.	Dimorphic Fungi	Not Evaluable	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Disease Category.	Aspergillus Syndromes	Success	12 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Disease Category.	Aspergillus Syndromes	Failure	23 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Disease Category.	Aspergillus Syndromes	Not Evaluable	5 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Disease Category.	Other emerging fungi	Success	7 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Disease Category.	Other emerging fungi	Failure	3 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Disease Category.	Other emerging fungi	Not Evaluable	1 Participants

Secondary

Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Enrollment Category

The percentage of participants who achieve a Global Response (defined as complete or partial response) as determined by the DRC by enrollment category, at disease specific timepoints. Global Response is measured by participant survival and overall effect of treatment on the disease. Complete response: Survival, all attributable signs/symptoms (including radiological) resolved and myoclogical eradication of disease; Partial response: Survival, improvement of attributable signs/symptoms (including radiological). Disease specific timepoints: End of Treatment (EoT) for invasive candidiasis, EoT or Day 84 for Chronic Mucocutaneous Candidiasis, Test of Cure (TOC) for Vulvovaginal Candidiasis, EoT or Day 90 for Chronic Pulmonary Aspergillosis, EoT or Day 90 Allergic Bronchopulmonary Aspergillosis and EoT for all other diseases. Participants may have been enrolled for more than 1 enrollment reason.

Population: Intent to Treat (ITT) Population - all participants who were enrolled in the study and received at least one dose of study drug.

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Enrollment Category	Refractory Fungal Infection	Success	74 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Enrollment Category	Refractory Fungal Infection	Failure	41 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Enrollment Category	Refractory Fungal Infection	Not Evaluable	13 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Enrollment Category	Resistance to standard of care antifungal	Success	95 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Enrollment Category	Resistance to standard of care antifungal	Failure	29 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Enrollment Category	Resistance to standard of care antifungal	Not Evaluable	10 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Enrollment Category	Intolerance to standard of care antifungal	Success	13 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Enrollment Category	Intolerance to standard of care antifungal	Failure	14 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Enrollment Category	Intolerance to standard of care antifungal	Not Evaluable	2 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Enrollment Category	Toxicities associated with standard of care antifungal	Success	7 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Enrollment Category	Toxicities associated with standard of care antifungal	Failure	8 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Enrollment Category	Toxicities associated with standard of care antifungal	Not Evaluable	2 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Enrollment Category	Relapse	Success	12 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Enrollment Category	Relapse	Failure	5 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Enrollment Category	Relapse	Not Evaluable	1 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Enrollment Category	Other	Success	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Enrollment Category	Other	Failure	1 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Enrollment Category	Other	Not Evaluable	1 Participants

Secondary

Percentage of Participants With a Clinical Response (Based on Signs and Symptoms) by Disease Category

The percentage of participants with a Clinical Response as determined by the DRC at disease specific timepoints, by disease category. Clinical Response: resolution or improvement in attributable symptoms and signs of disease and radiological abnormalities (if applicable) . Disease specific timepoints: End of Treatment (EoT) for invasive candidiasis, EoT or Day 84 for Chronic Mucocutaneous Candidiasis, Test of Cure (TOC) for Vulvovaginal Candidiasis, EoT or Day 90 for Chronic Pulmonary Aspergillosis, EoT or Day 90 Allergic Bronchopulmonary Aspergillosis and EoT for all other diseases. Clinical response was evaluated based on disease signs (including radiological signs) and symptoms.

Population: Intent to Treat (ITT) includes all participants enrolled in the study who received at lease one dose of study drug.

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Based on Signs and Symptoms) by Disease Category	Invasive Candidiasis including Candidemia	Success	57 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Based on Signs and Symptoms) by Disease Category	Invasive Candidiasis including Candidemia	Failure	16 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Based on Signs and Symptoms) by Disease Category	Invasive Candidiasis including Candidemia	Not Evaluable	29 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Based on Signs and Symptoms) by Disease Category	Invasive Candidiasis including Candidemia	No Response	2 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Based on Signs and Symptoms) by Disease Category	Mucocutaneous Candidiasis (TOC)	Success	25 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Based on Signs and Symptoms) by Disease Category	Mucocutaneous Candidiasis (TOC)	Failure	5 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Based on Signs and Symptoms) by Disease Category	Mucocutaneous Candidiasis (TOC)	Not Evaluable	2 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Based on Signs and Symptoms) by Disease Category	Mucocutaneous Candidiasis (TOC)	No Response	43 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Based on Signs and Symptoms) by Disease Category	Dimorphic Fungi	Success	3 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Based on Signs and Symptoms) by Disease Category	Dimorphic Fungi	Failure	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Based on Signs and Symptoms) by Disease Category	Dimorphic Fungi	Not Evaluable	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Based on Signs and Symptoms) by Disease Category	Dimorphic Fungi	No Response	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Based on Signs and Symptoms) by Disease Category	Aspergillus Syndromes	Success	18 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Based on Signs and Symptoms) by Disease Category	Aspergillus Syndromes	Failure	14 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Based on Signs and Symptoms) by Disease Category	Aspergillus Syndromes	Not Evaluable	6 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Based on Signs and Symptoms) by Disease Category	Aspergillus Syndromes	No Response	2 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Based on Signs and Symptoms) by Disease Category	Other emerging fungi	Success	7 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Based on Signs and Symptoms) by Disease Category	Other emerging fungi	Failure	3 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Based on Signs and Symptoms) by Disease Category	Other emerging fungi	Not Evaluable	1 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Based on Signs and Symptoms) by Disease Category	Other emerging fungi	No Response	0 Participants

Secondary

Percentage of Participants With a Clinical Response (Signs and Symptoms) by Disease Category and Pathogen

The percentage of participants with a Clinical Response as determined by the DRC by disease category and by pathogen isolated, at disease specific timepoints. Clinical Response: resolution or improvement in attributable symptoms and signs of disease and radiological abnormalities (if applicable) . Disease specific timepoints: End of Treatment (EoT) for invasive candidiasis, EoT or Day 84 for Chronic Mucocutaneous Candidiasis, Test of Cure (TOC) for Vulvovaginal Candidiasis, EoT or Day 90 for Chronic Pulmonary Aspergillosis, EoT or Day 90 Allergic Bronchopulmonary Aspergillosis and EoT for all other diseases. Clinical response was evaluated based on disease signs (including radiological signs) and symptoms.

Population: Intent to Treat (ITT) includes all participants enrolled in the study who received at lease one dose of study drug.

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Disease Category and Pathogen	Invasive Candidiasis, including Candidemia (other)	Not Evaluable/Missing	2 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Disease Category and Pathogen	Invasive Candidiasis, including Candidemia (C. auris)	Success	6 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Disease Category and Pathogen	Invasive Candidiasis, including Candidemia (C. auris)	Failure	1 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Disease Category and Pathogen	Invasive Candidiasis, including Candidemia (C. auris)	Not Evaluable/Missing	3 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Disease Category and Pathogen	Invasive Candidiasis, including Candidemia (C. glabrata)	Success	30 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Disease Category and Pathogen	Invasive Candidiasis, including Candidemia (C. glabrata)	Failure	6 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Disease Category and Pathogen	Invasive Candidiasis, including Candidemia (C. glabrata)	Not Evaluable/Missing	13 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Disease Category and Pathogen	Invasive Candidiasis, including Candidemia (C. krusei)	Success	4 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Disease Category and Pathogen	Invasive Candidiasis, including Candidemia (C. krusei)	Failure	2 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Disease Category and Pathogen	Invasive Candidiasis, including Candidemia (C. krusei)	Not Evaluable/Missing	2 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Disease Category and Pathogen	Invasive Candidiasis, including Candidemia (C. parapsilosis)	Success	5 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Disease Category and Pathogen	Invasive Candidiasis, including Candidemia (C. parapsilosis)	Failure	1 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Disease Category and Pathogen	Invasive Candidiasis, including Candidemia (C. parapsilosis)	Not Evaluable/Missing	3 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Disease Category and Pathogen	Invasive Candidiasis, including Candidemia (C. tropicalis)	Success	6 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Disease Category and Pathogen	Invasive Candidiasis, including Candidemia (C. tropicalis)	Failure	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Disease Category and Pathogen	Invasive Candidiasis, including Candidemia (C. tropicalis)	Not Evaluable/Missing	3 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Disease Category and Pathogen	Invasive Candidiasis, including Candidemia (other)	Success	3 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Disease Category and Pathogen	Invasive Candidiasis, including Candidemia (other)	Failure	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Disease Category and Pathogen	Mucocutaneous Candidiasis (C. albicans)	Success	19 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Disease Category and Pathogen	Mucocutaneous Candidiasis (C. albicans)	Failure	1 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Disease Category and Pathogen	Mucocutaneous Candidiasis (C. albicans)	Not Evaluable/Missing	27 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Disease Category and Pathogen	Mucocutaneous Candidiasis (C. glabrata)	Success	5 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Disease Category and Pathogen	Mucocutaneous Candidiasis (C. glabrata)	Failure	3 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Disease Category and Pathogen	Mucocutaneous Candidiasis (C. glabrata)	Not Evaluable/Missing	17 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Disease Category and Pathogen	Mucocutaneous Candidiasis (C. krusei)	Success	2 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Disease Category and Pathogen	Mucocutaneous Candidiasis (C. krusei)	Failure	1 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Disease Category and Pathogen	Mucocutaneous Candidiasis (C. krusei)	Not Evaluable/Missing	4 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Disease Category and Pathogen	Mucocutaneous Candidiasis (C. tropicalis)	Success	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Disease Category and Pathogen	Mucocutaneous Candidiasis (C. tropicalis)	Failure	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Disease Category and Pathogen	Mucocutaneous Candidiasis (C. tropicalis)	Not Evaluable/Missing	1 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Disease Category and Pathogen	Mucocutaneous Candidiasis (C. parapsilosis)	Success	1 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Disease Category and Pathogen	Mucocutaneous Candidiasis (C. parapsilosis)	Failure	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Disease Category and Pathogen	Mucocutaneous Candidiasis (C. parapsilosis)	Not Evaluable/Missing	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Disease Category and Pathogen	Mucocutaneous Candidiasis (other)	Success	3 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Disease Category and Pathogen	Mucocutaneous Candidiasis (other)	Failure	1 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Disease Category and Pathogen	Mucocutaneous Candidiasis (other)	Not Evaluable/Missing	5 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Disease Category and Pathogen	Dimorphic Fungi (Histoplasmosis)	Success	3 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Disease Category and Pathogen	Dimorphic Fungi (Histoplasmosis)	Failure	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Disease Category and Pathogen	Dimorphic Fungi (Histoplasmosis)	Not Evaluable/Missing	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Disease Category and Pathogen	Aspergillus Syndromes (A. flavus)	Success	2 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Disease Category and Pathogen	Aspergillus Syndromes (A. flavus)	Failure	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Disease Category and Pathogen	Aspergillus Syndromes (A. flavus)	Not Evaluable/Missing	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Disease Category and Pathogen	Aspergillus Syndromes (A. fumigatus)	Success	8 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Disease Category and Pathogen	Aspergillus Syndromes (A. fumigatus)	Failure	8 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Disease Category and Pathogen	Aspergillus Syndromes (A. fumigatus)	Not Evaluable/Missing	2 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Disease Category and Pathogen	Aspergillus Syndromes (other)	Success	9 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Disease Category and Pathogen	Aspergillus Syndromes (other)	Failure	5 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Disease Category and Pathogen	Aspergillus Syndromes (other)	Not Evaluable/Missing	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Disease Category and Pathogen	Invasive Candidiasis, including Candidemia (C. albicans)	Success	11 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Disease Category and Pathogen	Invasive Candidiasis, including Candidemia (C. albicans)	Failure	7 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Disease Category and Pathogen	Invasive Candidiasis, including Candidemia (C. albicans)	Not Evaluable/Missing	8 Participants

Secondary

Percentage of Participants With a Clinical Response (Signs and Symptoms) by Enrollment Category

The percentage of participants with a Clinical Response as determined by the DRC by enrollment category, at disease specific timepoints. Clinical Response: resolution or improvement in attributable symptoms and signs of disease and radiological abnormalities (if applicable) . Disease specific timepoints: End of Treatment (EoT) for invasive candidiasis, EoT or Day 84 for Chronic Mucocutaneous Candidiasis, Test of Cure (TOC) for Vulvovaginal Candidiasis, EoT or Day 90 for Chronic Pulmonary Aspergillosis, EoT or Day 90 Allergic Bronchopulmonary Aspergillosis and EoT for all other diseases. Clinical response was evaluated based on disease signs (including radiological signs) and symptoms.

Population: Intent to Treat (ITT) includes all participants enrolled in the study who received at lease one dose of study drug.

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Enrollment Category	Relapse	Success	8 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Enrollment Category	Refractory	Success	57 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Enrollment Category	Refractory	Failure	29 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Enrollment Category	Refractory	Not Evaluable	13 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Enrollment Category	Refractory	No Response	29 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Enrollment Category	Resistence	Success	75 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Enrollment Category	Resistence	Failure	23 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Enrollment Category	Resistence	Not Evaluable	25 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Enrollment Category	Resistence	No Response	11 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Enrollment Category	Intolerance	Success	16 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Enrollment Category	Intolerance	Failure	8 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Enrollment Category	Intolerance	Not Evaluable	3 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Enrollment Category	Toxicities	No Response	1 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Enrollment Category	Intolerance	No Response	2 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Enrollment Category	Toxicities	Success	12 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Enrollment Category	Toxicities	Failure	3 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Enrollment Category	Toxicities	Not Evaluable	1 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Enrollment Category	Relapse	Failure	4 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Enrollment Category	Relapse	Not Evaluable	1 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Enrollment Category	Relapse	No Response	5 Participants

Secondary

Percentage of Participants With a Clinical Response (Signs and Symptoms) by Fungal Disease

The percentage of participants with a Clinical Response as determined by the DRC by fungal disease, at disease specific timepoints. Clinical Response: resolution or improvement in attributable symptoms and signs of disease and radiological abnormalities (if applicable) . Disease specific timepoints: End of Treatment (EoT) for invasive candidiasis, EoT or Day 84 for Chronic Mucocutaneous Candidiasis, Test of Cure (TOC) for Vulvovaginal Candidiasis, EoT or Day 90 for Chronic Pulmonary Aspergillosis, EoT or Day 90 Allergic Bronchopulmonary Aspergillosis and EoT for all other diseases. Clinical response was evaluated based on disease signs (including radiological signs) and symptoms.

Population: Intent to Treat (ITT) includes all participants enrolled in the study who received at lease one dose of study drug.

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Fungal Disease	Acute Invasive Candidiasis, including Candidemia	Success	30 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Fungal Disease	Acute Invasive Candidiasis, including Candidemia	Failure	10 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Fungal Disease	Acute Invasive Candidiasis, including Candidemia	Not Evaluable	19 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Fungal Disease	Acute Invasive Candidiasis, including Candidemia	No Response	2 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Fungal Disease	Chronic Invasive Candidiasis	Success	27 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Fungal Disease	Chronic Invasive Candidiasis	Failure	6 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Fungal Disease	Chronic Invasive Candidiasis	Not Evaluable	10 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Fungal Disease	Chronic Invasive Candidiasis	No Response	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Fungal Disease	Vulvovaginal Candidiasis	Success	25 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Fungal Disease	Vulvovaginal Candidiasis	Failure	5 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Fungal Disease	Vulvovaginal Candidiasis	Not Evaluable	2 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Fungal Disease	Vulvovaginal Candidiasis	No Response	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Fungal Disease	Esophageal Candidiasis	Success	10 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Fungal Disease	Esophageal Candidiasis	Failure	4 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Fungal Disease	Esophageal Candidiasis	Not Evaluable	2 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Fungal Disease	Esophageal Candidiasis	No Response	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Fungal Disease	Oropharyngeal Candidiasis	Success	10 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Fungal Disease	Oropharyngeal Candidiasis	Failure	4 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Fungal Disease	Oropharyngeal Candidiasis	Not Evaluable	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Fungal Disease	Oropharyngeal Candidiasis	No Response	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Fungal Disease	Chronic Mucocutaneous Candidiasis	Success	8 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Fungal Disease	Chronic Mucocutaneous Candidiasis	Failure	5 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Fungal Disease	Chronic Mucocutaneous Candidiasis	Not Evaluable	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Fungal Disease	Chronic Mucocutaneous Candidiasis	No Response	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Fungal Disease	Disseminated/Invasive Dimorphic Fungi	Success	3 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Fungal Disease	Disseminated/Invasive Dimorphic Fungi	Failure	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Fungal Disease	Disseminated/Invasive Dimorphic Fungi	Not Evaluable	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Fungal Disease	Disseminated/Invasive Dimorphic Fungi	No Response	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Fungal Disease	Chronic Pulmonary Aspergillosis	Success	3 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Fungal Disease	Chronic Pulmonary Aspergillosis	Failure	2 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Fungal Disease	Chronic Pulmonary Aspergillosis	Not Evaluable	1 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Fungal Disease	Chronic Pulmonary Aspergillosis	No Response	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Fungal Disease	Allergic Bronchopulmonary Aspergillosis	Success	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Fungal Disease	Allergic Bronchopulmonary Aspergillosis	Failure	2 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Fungal Disease	Allergic Bronchopulmonary Aspergillosis	Not Evaluable	2 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Fungal Disease	Allergic Bronchopulmonary Aspergillosis	No Response	1 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Fungal Disease	Invasive Pulmonary Aspergillosis	Success	15 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Fungal Disease	Invasive Pulmonary Aspergillosis	Failure	10 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Fungal Disease	Invasive Pulmonary Aspergillosis	Not Evaluable	3 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Fungal Disease	Invasive Pulmonary Aspergillosis	No Response	1 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Fungal Disease	Other Emerging Fungi	Success	7 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Fungal Disease	Other Emerging Fungi	Failure	3 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Fungal Disease	Other Emerging Fungi	Not Evaluable	1 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Clinical Response (Signs and Symptoms) by Fungal Disease	Other Emerging Fungi	No Response	0 Participants

Secondary

Percentage of Participants With a Mycological Response by Disease Category

The percentage of participants with a Mycological Response as determined by the DRC by disease category, at disease specific timepoints. Mycological Response: evidence of eradication or clearance of cultures or reduction of fungal burden, as assessed by a quantitative and validated laboratory marker. Disease specific timepoints: End of Treatment (EoT) for invasive candidiasis, EoT or Day 84 for Chronic Mucocutaneous Candidiasis, Test of Cure (TOC) for Vulvovaginal Candidiasis, EoT or Day 90 for Chronic Pulmonary Aspergillosis, EoT or Day 90 Allergic Bronchopulmonary Aspergillosis and EoT for all other diseases. Mycological response was evaluated based on culture, microscopy and other biomarkers of fungal infection.

Population: Intent to Treat (ITT) includes all participants enrolled in the study who received at lease one dose of study drug.

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Disease Category	Dimorphic Fungi	Not Evaluable/Missing	2 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Disease Category	Invasive Candidiasis including Candidemia	Success	20 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Disease Category	Invasive Candidiasis including Candidemia	Failure	14 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Disease Category	Invasive Candidiasis including Candidemia	Not Evaluable/Missing	70 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Disease Category	Mucocutaneous Candidiasis (TOC)	Success	11 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Disease Category	Mucocutaneous Candidiasis (TOC)	Failure	13 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Disease Category	Mucocutaneous Candidiasis (TOC)	Not Evaluable/Missing	51 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Disease Category	Dimorphic Fungi	Success	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Disease Category	Dimorphic Fungi	Failure	1 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Disease Category	Aspergillus Syndromes	Success	5 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Disease Category	Aspergillus Syndromes	Failure	13 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Disease Category	Aspergillus Syndromes	Not Evaluable/Missing	22 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Disease Category	Other emerging fungi	Success	2 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Disease Category	Other emerging fungi	Failure	2 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Disease Category	Other emerging fungi	Not Evaluable/Missing	7 Participants

Secondary

Percentage of Participants With a Mycological Response by Disease Category and Pathogen

The percentage of participants with a Mycological Response as determined by the DRC by disease category and by pathogen, at disease specific timepoints. Mycological Response: evidence of eradication or clearance of cultures or reduction of fungal burden, as assessed by a quantitative and validated laboratory marker. Disease specific timepoints: End of Treatment (EoT) for invasive candidiasis, EoT or Day 84 for Chronic Mucocutaneous Candidiasis, Test of Cure (TOC) for Vulvovaginal Candidiasis, EoT or Day 90 for Chronic Pulmonary Aspergillosis, EoT or Day 90 Allergic Bronchopulmonary Aspergillosis and EoT for all other diseases. Mycological response was evaluated based on culture, microscopy and other biomarkers of fungal infection.

Population: Intent to Treat (ITT) includes all participants enrolled in the study who received at lease one dose of study drug.

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Disease Category and Pathogen	Invasive Candidiasis, including Candidemia (C. glabrata)	Success	10 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Disease Category and Pathogen	Invasive Candidiasis, including Candidemia (other)	Success	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Disease Category and Pathogen	Dimorphic Fungi (Histoplasmosis)	Not Evaluable/Missing	2 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Disease Category and Pathogen	Invasive Candidiasis, including Candidemia (C. albicans)	Success	3 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Disease Category and Pathogen	Invasive Candidiasis, including Candidemia (C. albicans)	Failure	6 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Disease Category and Pathogen	Invasive Candidiasis, including Candidemia (C. albicans)	Not Evaluable/Missing	17 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Disease Category and Pathogen	Invasive Candidiasis, including Candidemia (C. parapsilosis)	Success	1 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Disease Category and Pathogen	Invasive Candidiasis, including Candidemia (C. parapsilosis)	Failure	2 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Disease Category and Pathogen	Invasive Candidiasis, including Candidemia (C. parapsilosis)	Not Evaluable/Missing	6 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Disease Category and Pathogen	Invasive Candidiasis, including Candidemia (C. auris)	Success	2 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Disease Category and Pathogen	Invasive Candidiasis, including Candidemia (C. auris)	Failure	1 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Disease Category and Pathogen	Invasive Candidiasis, including Candidemia (C. auris)	Not Evaluable/Missing	7 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Disease Category and Pathogen	Invasive Candidiasis, including Candidemia (C. glabrata)	Failure	7 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Disease Category and Pathogen	Invasive Candidiasis, including Candidemia (C. glabrata)	Not Evaluable/Missing	32 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Disease Category and Pathogen	Invasive Candidiasis, including Candidemia (C. krusei)	Success	5 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Disease Category and Pathogen	Invasive Candidiasis, including Candidemia (C. krusei)	Failure	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Disease Category and Pathogen	Invasive Candidiasis, including Candidemia (C. krusei)	Not Evaluable/Missing	3 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Disease Category and Pathogen	Invasive Candidiasis, including Candidemia (C. tropicalis)	Success	2 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Disease Category and Pathogen	Invasive Candidiasis, including Candidemia (C. tropicalis)	Failure	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Disease Category and Pathogen	Invasive Candidiasis, including Candidemia (C. tropicalis)	Not Evaluable/Missing	7 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Disease Category and Pathogen	Invasive Candidiasis, including Candidemia (other)	Failure	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Disease Category and Pathogen	Invasive Candidiasis, including Candidemia (other)	Not Evaluable/Missing	5 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Disease Category and Pathogen	Mucocutaneous Candidiasis (C. albicans)	Success	10 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Disease Category and Pathogen	Mucocutaneous Candidiasis (C. albicans)	Failure	5 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Disease Category and Pathogen	Mucocutaneous Candidiasis (C. albicans)	Not Evaluable/Missing	32 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Disease Category and Pathogen	Mucocutaneous Candidiasis (C. glabrata)	Success	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Disease Category and Pathogen	Mucocutaneous Candidiasis (C. krusei)	Success	2 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Disease Category and Pathogen	Mucocutaneous Candidiasis (C. glabrata)	Failure	8 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Disease Category and Pathogen	Mucocutaneous Candidiasis (C. glabrata)	Not Evaluable/Missing	17 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Disease Category and Pathogen	Mucocutaneous Candidiasis (C. krusei)	Failure	1 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Disease Category and Pathogen	Mucocutaneous Candidiasis (C. krusei)	Not Evaluable/Missing	4 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Disease Category and Pathogen	Mucocutaneous Candidiasis (C. parapsilosis)	Success	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Disease Category and Pathogen	Mucocutaneous Candidiasis (C. parapsilosis)	Failure	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Disease Category and Pathogen	Mucocutaneous Candidiasis (C. parapsilosis)	Not Evaluable/Missing	1 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Disease Category and Pathogen	Mucocutaneous Candidiasis (C. tropicalis)	Success	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Disease Category and Pathogen	Mucocutaneous Candidiasis (C. tropicalis)	Failure	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Disease Category and Pathogen	Mucocutaneous Candidiasis (C. tropicalis)	Not Evaluable/Missing	1 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Disease Category and Pathogen	Mucocutaneous Candidiasis other)	Success	2 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Disease Category and Pathogen	Mucocutaneous Candidiasis other)	Failure	2 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Disease Category and Pathogen	Mucocutaneous Candidiasis other)	Not Evaluable/Missing	5 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Disease Category and Pathogen	Dimorphic Fungi (Coccidioidomycosis)	Success	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Disease Category and Pathogen	Dimorphic Fungi (Coccidioidomycosis)	Failure	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Disease Category and Pathogen	Dimorphic Fungi (Coccidioidomycosis)	Not Evaluable/Missing	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Disease Category and Pathogen	Dimorphic Fungi (Histoplasmosis)	Success	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Disease Category and Pathogen	Dimorphic Fungi (Histoplasmosis)	Failure	1 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Disease Category and Pathogen	Aspergillus Syndromes (A. nidulans)	Success	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Disease Category and Pathogen	Aspergillus Syndromes (A. nidulans)	Failure	1 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Disease Category and Pathogen	Aspergillus Syndromes (A. nidulans)	Not Evaluable/Missing	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Disease Category and Pathogen	Aspergillus Syndromes (A. fumigatus)	Success	1 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Disease Category and Pathogen	Aspergillus Syndromes (A. fumigatus)	Failure	5 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Disease Category and Pathogen	Aspergillus Syndromes (A. fumigatus)	Not Evaluable/Missing	12 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Disease Category and Pathogen	Aspergillus Syndromes (A. flavus)	Success	1 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Disease Category and Pathogen	Aspergillus Syndromes (A. flavus)	Failure	1 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Disease Category and Pathogen	Aspergillus Syndromes (A. flavus)	Not Evaluable/Missing	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Disease Category and Pathogen	Aspergillus Syndromes (other)	Success	2 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Disease Category and Pathogen	Aspergillus Syndromes (other)	Failure	7 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Disease Category and Pathogen	Aspergillus Syndromes (other)	Not Evaluable/Missing	5 Participants

Secondary

Percentage of Participants With a Mycological Response by Enrollment Category

The percentage of participants with a Mycological Response as determined by the DRC by enrollment category, at disease specific timepoints. Mycological Response: evidence of eradication or clearance of cultures or reduction of fungal burden, as assessed by a quantitative and validated laboratory marker. Disease specific timepoints: End of Treatment (EoT) for invasive candidiasis, EoT or Day 84 for Chronic Mucocutaneous Candidiasis, Test of Cure (TOC) for Vulvovaginal Candidiasis, EoT or Day 90 for Chronic Pulmonary Aspergillosis, EoT or Day 90 Allergic Bronchopulmonary Aspergillosis and EoT for all other diseases. Mycological response was evaluated based on culture, microscopy and other biomarkers of fungal infection.

Population: Intent to Treat (ITT) includes all participants enrolled in the study who received at lease one dose of study drug.

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Enrollment Category	Refractory	Success	21 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Enrollment Category	Refractory	Failure	33 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Enrollment Category	Refractory	Not Evaluable/Failure	74 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Enrollment Category	Resistence	Success	28 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Enrollment Category	Resistence	Failure	19 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Enrollment Category	Resistence	Not Evaluable/Failure	87 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Enrollment Category	Intolerance	Success	7 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Enrollment Category	Intolerance	Failure	10 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Enrollment Category	Intolerance	Not Evaluable/Failure	12 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Enrollment Category	Toxicities	Success	1 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Enrollment Category	Toxicities	Failure	5 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Enrollment Category	Toxicities	Not Evaluable/Failure	11 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Enrollment Category	Relapse	Success	5 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Enrollment Category	Relapse	Failure	2 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Enrollment Category	Relapse	Not Evaluable/Failure	11 Participants

Secondary

Percentage of Participants With a Mycological Response by Fungal Disease

The percentage of participants with a Mycological Response as determined by the DRC by fungal disease, at disease specific timepoints. Mycological Response: evidence of eradication or clearance of cultures or reduction of fungal burden, as assessed by a quantitative and validated laboratory marker. Disease specific timepoints: End of Treatment (EoT) for invasive candidiasis, EoT or Day 84 for Chronic Mucocutaneous Candidiasis, Test of Cure (TOC) for Vulvovaginal Candidiasis, EoT or Day 90 for Chronic Pulmonary Aspergillosis, EoT or Day 90 Allergic Bronchopulmonary Aspergillosis and EoT for all other diseases. Mycological response was evaluated based on culture, microscopy and other biomarkers of fungal infection.

Population: Intent to Treat (ITT) includes all participants enrolled in the study who received at lease one dose of study drug.

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Fungal Disease	Acute Invasive Candidiasis, including Candidemia	Success	16 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Fungal Disease	Acute Invasive Candidiasis, including Candidemia	Failure	10 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Fungal Disease	Acute Invasive Candidiasis, including Candidemia	Not Evaluable/Missing	35 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Fungal Disease	Chronic Invasive Candidiasis	Success	4 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Fungal Disease	Chronic Invasive Candidiasis	Failure	4 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Fungal Disease	Chronic Invasive Candidiasis	Not Evaluable/Missing	35 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Fungal Disease	Esophageal Candidiasis	Success	2 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Fungal Disease	Esophageal Candidiasis	Failure	5 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Fungal Disease	Esophageal Candidiasis	Not Evaluable/Missing	9 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Fungal Disease	Oropharyngeal Candidiasis	Success	7 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Fungal Disease	Oropharyngeal Candidiasis	Failure	4 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Fungal Disease	Oropharyngeal Candidiasis	Not Evaluable/Missing	3 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Fungal Disease	Chronic Mucocutaneous Candidiasis	Success	6 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Fungal Disease	Chronic Mucocutaneous Candidiasis	Failure	6 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Fungal Disease	Chronic Mucocutaneous Candidiasis	Not Evaluable/Missing	1 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Fungal Disease	Vulvovaginal Candidiasis	Success	11 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Fungal Disease	Vulvovaginal Candidiasis	Failure	13 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Fungal Disease	Vulvovaginal Candidiasis	Not Evaluable/Missing	8 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Fungal Disease	Disseminated/Invasive Dimorphic Fungi	Success	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Fungal Disease	Disseminated/Invasive Dimorphic Fungi	Failure	1 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Fungal Disease	Disseminated/Invasive Dimorphic Fungi	Not Evaluable/Missing	2 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Fungal Disease	Chronic Pulmonary Aspergillosis	Success	1 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Fungal Disease	Chronic Pulmonary Aspergillosis	Failure	4 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Fungal Disease	Chronic Pulmonary Aspergillosis	Not Evaluable/Missing	1 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Fungal Disease	Allergic Bronchopulmonary Aspergillosis	Success	1 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Fungal Disease	Allergic Bronchopulmonary Aspergillosis	Failure	2 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Fungal Disease	Allergic Bronchopulmonary Aspergillosis	Not Evaluable/Missing	2 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Fungal Disease	Invasive Pulmonary Aspergillosis	Success	3 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Fungal Disease	Invasive Pulmonary Aspergillosis	Failure	7 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Fungal Disease	Invasive Pulmonary Aspergillosis	Not Evaluable/Missing	19 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Fungal Disease	Other Emerging Fungi	Success	2 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Fungal Disease	Other Emerging Fungi	Failure	2 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Mycological Response by Fungal Disease	Other Emerging Fungi	Not Evaluable/Missing	7 Participants

Secondary

Percentage of Participants With a Recurrence of Baseline Fungal Disease

The percentage of participants with a recurrence of their baseline fungal disease as assessed by the DRC at the 25-Day Follow Up (FU) for Vulvovaginal Candidiasis and at the 6-Week FU for all other diseases as assessed by the DRC. Recurrence is defined as having Global Response at end of treatment or test of cure, but re-emergence of the baseline fungal disease during the post treatment follow-up. Re-emergence is required to be with the same species and involving the same site identified at baseline.

Time frame: 42 days for vulvovaginal candidiasis and 6 weeks after End of Treatment (up to 180 days after treatment start) for all other diseases.

Population: Intent to Treat (ITT) population (any participant who was enrolled in the study and received at least one dose of study drug) that achieved a Global Response.

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
Ibrexafungerp (SCY-078)	Percentage of Participants With a Recurrence of Baseline Fungal Disease	Acute Invasive Candidiasis including Candidemia	Recurrence	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Recurrence of Baseline Fungal Disease	Acute Invasive Candidiasis including Candidemia	No Recurrence	35 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Recurrence of Baseline Fungal Disease	Acute Invasive Candidiasis including Candidemia	Not Evaluable	5 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Recurrence of Baseline Fungal Disease	Chronic Invasive Candidasis	Recurrence	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Recurrence of Baseline Fungal Disease	Chronic Invasive Candidasis	No Recurrence	29 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Recurrence of Baseline Fungal Disease	Chronic Invasive Candidasis	Not Evaluable	1 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Recurrence of Baseline Fungal Disease	Candidemia only	Recurrence	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Recurrence of Baseline Fungal Disease	Candidemia only	No Recurrence	11 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Recurrence of Baseline Fungal Disease	Candidemia only	Not Evaluable	2 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Recurrence of Baseline Fungal Disease	Esophageal Candidiasis	Recurrence	3 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Recurrence of Baseline Fungal Disease	Esophageal Candidiasis	No Recurrence	5 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Recurrence of Baseline Fungal Disease	Esophageal Candidiasis	Not Evaluable	1 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Recurrence of Baseline Fungal Disease	Oropharyngeal Candidiasis	Recurrence	2 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Recurrence of Baseline Fungal Disease	Oropharyngeal Candidiasis	No Recurrence	7 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Recurrence of Baseline Fungal Disease	Oropharyngeal Candidiasis	Not Evaluable	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Recurrence of Baseline Fungal Disease	Chronic Mucotaneous Candidiasis	Recurrence	4 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Recurrence of Baseline Fungal Disease	Chronic Mucotaneous Candidiasis	No Recurrence	2 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Recurrence of Baseline Fungal Disease	Chronic Mucotaneous Candidiasis	Not Evaluable	1 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Recurrence of Baseline Fungal Disease	Vulvovaginal Candidiasis	Recurrence	6 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Recurrence of Baseline Fungal Disease	Vulvovaginal Candidiasis	No Recurrence	18 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Recurrence of Baseline Fungal Disease	Vulvovaginal Candidiasis	Not Evaluable	4 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Recurrence of Baseline Fungal Disease	Disseminated/Invasive Dimorphic Fungi	Recurrence	1 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Recurrence of Baseline Fungal Disease	Disseminated/Invasive Dimorphic Fungi	No Recurrence	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Recurrence of Baseline Fungal Disease	Disseminated/Invasive Dimorphic Fungi	Not Evaluable	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Recurrence of Baseline Fungal Disease	Chronic Pulmonary Aspergillosis	Recurrence	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Recurrence of Baseline Fungal Disease	Chronic Pulmonary Aspergillosis	No Recurrence	1 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Recurrence of Baseline Fungal Disease	Chronic Pulmonary Aspergillosis	Not Evaluable	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Recurrence of Baseline Fungal Disease	Allergic Bronchopulmonary Aspergillosis	Recurrence	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Recurrence of Baseline Fungal Disease	Allergic Bronchopulmonary Aspergillosis	No Recurrence	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Recurrence of Baseline Fungal Disease	Allergic Bronchopulmonary Aspergillosis	Not Evaluable	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Recurrence of Baseline Fungal Disease	Invasive Pulmonary Aspergillosis	Recurrence	2 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Recurrence of Baseline Fungal Disease	Invasive Pulmonary Aspergillosis	No Recurrence	10 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Recurrence of Baseline Fungal Disease	Invasive Pulmonary Aspergillosis	Not Evaluable	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Recurrence of Baseline Fungal Disease	Other	Recurrence	0 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Recurrence of Baseline Fungal Disease	Other	No Recurrence	6 Participants
Ibrexafungerp (SCY-078)	Percentage of Participants With a Recurrence of Baseline Fungal Disease	Other	Not Evaluable	1 Participants

Secondary

Time to Death From Any Cause

Time to death from any cause in days per Fungal Disease

Time frame: Six weeks after End of Treatment (EOT). EOT for Vulvovaginal Candidiasis is Day 7, Chronic Mucocutaneous Candidiasis is up to Day 84, Chronic Pulmonary Aspergillus and Allergic Bronchopulmonary Aspergillosis is up to Day 90 and up to Day 180 for other.

Population: Safety Population - All subjects who received at least one dose of study drug and who had at least one safety assessment post-Baseline.

Arm	Measure	Group	Value (MEDIAN)
Ibrexafungerp (SCY-078)	Time to Death From Any Cause	Acute Invasive Candidiasis	NA Number of days
Ibrexafungerp (SCY-078)	Time to Death From Any Cause	Candidemia	NA Number of days
Ibrexafungerp (SCY-078)	Time to Death From Any Cause	Chronic Invasive Candidiasis	NA Number of days
Ibrexafungerp (SCY-078)	Time to Death From Any Cause	Vulvovaginal Candidiasis	NA Number of days
Ibrexafungerp (SCY-078)	Time to Death From Any Cause	Esophageal Candidiasis	NA Number of days
Ibrexafungerp (SCY-078)	Time to Death From Any Cause	Oropharyngeal Candidiasis	NA Number of days
Ibrexafungerp (SCY-078)	Time to Death From Any Cause	Chronic Mucocutaneous Candidiasis	NA Number of days
Ibrexafungerp (SCY-078)	Time to Death From Any Cause	Diffuse/Invasive Dimorphic Fungi	NA Number of days
Ibrexafungerp (SCY-078)	Time to Death From Any Cause	Chronic Pulmonary Aspergillosis	NA Number of days
Ibrexafungerp (SCY-078)	Time to Death From Any Cause	Allergic Bronchopulmonary Aspergillosis	NA Number of days
Ibrexafungerp (SCY-078)	Time to Death From Any Cause	Invasive Pulmonary Aspergillosis	282 Number of days
Ibrexafungerp (SCY-078)	Time to Death From Any Cause	Other Emerging Fungi	270 Number of days

Source: ClinicalTrials.gov · Data processed: Feb 17, 2026

Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment

Conditions

Brief summary

Detailed description

Related papers

Interventions

Sponsors

Study design

Intervention model description

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Countries

Participant flow

Participants by arm

Baseline characteristics

Adverse events

Outcome results

Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.

Describe Ibrexafungerp Plasma Concentrations

Percentage of Participants Surviving at Day 30 or Day 42

Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Disease Category.

Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Enrollment Category

Percentage of Participants With a Clinical Response (Based on Signs and Symptoms) by Disease Category

Percentage of Participants With a Clinical Response (Signs and Symptoms) by Disease Category and Pathogen

Percentage of Participants With a Clinical Response (Signs and Symptoms) by Enrollment Category

Percentage of Participants With a Clinical Response (Signs and Symptoms) by Fungal Disease

Percentage of Participants With a Mycological Response by Disease Category

Percentage of Participants With a Mycological Response by Disease Category and Pathogen

Percentage of Participants With a Mycological Response by Enrollment Category

Percentage of Participants With a Mycological Response by Fungal Disease

Percentage of Participants With a Recurrence of Baseline Fungal Disease

Time to Death From Any Cause